71
Participants
Start Date
June 12, 2018
Primary Completion Date
May 5, 2022
Study Completion Date
May 5, 2022
TG02
"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
Radiation Therapy
For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
Temozolomide
For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH uniklinieken, Vienna
Erasmus MC Cancer Institute - location Daniel den Hoed, Rotterdam
UniversitaetsSpital Zurich, Zurich
Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone, Marseille
Universitaetsklinikum Bonn, Bonn
Klinikum Der J.W. Goethe Universitaet-Klinik und Poliklinik fur Neurochirurgie, Frankfurt
Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg
CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron
Universitaetskliniken Regensburg - Universitaetsklinikum Regensburg, Regensburg
CHRU de Lille, Lille
Tragara Pharmaceuticals, Inc.
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK